Group Therapy Supported Internet-based Cognitive Behavioral Therapy for Adolescents With Social Anxiety Disorder - A Feasibility Trial
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Social Anxiety Disorder
- Sponsor
- Karolinska Institutet
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Clinical Global Impression - Severity
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The primary objectives of this study is to test the feasibility and efficacy of group-therapy supported internet-delivered CBT for adolescents (13 - 17 years) with social anxiety disorder. Investigators will conduct an open trial with N = 30 participants. Participants will be assessed at baseline, immediately after treatment and at a 6-month follow-up.
Detailed Description
Social anxiety disorder (SAD) among youths is highly prevalent and causes significant impairment in the lives of the affected. In spite of CBT being the most effective treatment, evidence suggests that many young people with this disorder do not have access to good-quality CBT. Internet-based CBT is, as numerous prior studies have shown, an effective method to treat psychiatric conditions in adults, but little is known about ICBT for adolescents and there are but a few controlled studies on ICBT for children and adolescents with anxiety disorders. This pilot trial will evaluate the feasibility and efficacy of a blended ICBT-treatment where internet-based and group-based sessions are combined. Furthermore, as ICBT is a novel format in the treatment of psychological problems in young people, it is essential to evaluate the feasibility and acceptability of the technical solutions that carry the active treatment. The study will also include genotyping of participants to further our understanding of etiology of SAD and to explore the relationship between genetic variations and treatment outcome. Additionally, as there is little known about the affect of ASD symptoms on treatment outcome in face-to-face CBT in general, and in ICBT in particular, the association between autistic traits and treatment outcome will be evaluated. Lastly, the role of attentional processes in the maintenance of social anxiety has been scarcely studied and an aim with the current study is to further our understanding of the cognitive factors that underlie SAD
Investigators
Eva Serlachius
Associate professor, child psychiatrist, MD
Karolinska Institutet
Eligibility Criteria
Inclusion Criteria
- •A principal diagnosis of social anxiety disorder, as defined by DSM-5
- •Ability to read and write Swedish
- •Daily access to the internet through a computer or similar device
- •A parent or caregiver that is able to co-participate in the treatment
- •Participants on psychotropic medication must have been on a stable dose for the last 6 weeks prior to baseline assessment
Exclusion Criteria
- •Diagnosed with autism spectrum disorder, psychosis, bipolar disorder or severe eating disorder
- •Present risk of suicide
- •Ongoing substance dependence
- •Occurrence of domestic violence
- •Completed CBT for any anxiety disorder within the last 6 months (defined as at least 5 sessions of CBT including in vivo exposure sessions)
Outcomes
Primary Outcomes
Clinical Global Impression - Severity
Time Frame: Assessed at baseline, 12 weeks after treatment starts and 6 months after treatment has ended
Change from Baseline of social anxiety disorder severity, after 12 weeks and at 6 months after treatment
Secondary Outcomes
- DNA through saliva sampling(Assessed at baseline, 12 weeks after treatment starts and 6 months after treatment has ended)
- Technology acceptance scale (TAS) - parent version(Assessed at Mid-3 week and 12 weeks after treatment starts)
- Hospital Anxiety and Depression Scale (HADS)(Assessed at baseline.)
- Education, Work and Social Adjustment Scale - child version(Assessed at baseline, Mid-6 week, 12 weeks after treatment starts and 6 months after treatment has ended)
- Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - Child version (TiC-P)(Assessed at baseline, 12 weeks after treatment starts and 6 months after treatment has ended)
- Measurement of anxiety levels during exposure (app)(Assessed from Mid-4 week to 12 weeks after treatment starts)
- Clinical Global Impression - Improvement(Assessed 12 weeks after treatment starts and 6 months after treatment has ended)
- Children's Global Assessment Scale (CGAS)(Assessed at baseline, 12 weeks after treatment starts and 6 months after treatment has ended)
- KIDSCREEN-10 - Child version(Assessed at baseline, 12 weeks after treatment starts and 6 months after treatment has ended)
- Presence of DSM-5 Social Anxiety Disorder(Assessed at baseline, 12 weeks after treatment starts and 6 months after treatment has ended)
- Social Phobia and Anxiety Inventory (SPAI) - Child version(Assessed at baseline, Mid-3 weeks, Mid-6 weeks, Mid-9 weeks, 12 weeks after treatment starts and 6 months after treatment has ended)
- Revised Children´s Anxiety and Depression Scale (RCADS) - Child version(Assessed at baseline, Mid-6 weeks, 12 weeks after treatment starts and 6 months after treatment has ended)
- KIDSCREEN-10 - Parent version(Assessed at baseline, 12 weeks after treatment starts and 6 months after treatment has ended)
- Client Satisfaction Scale (CSS)(Assessed at 12 weeks after treatment starts)
- Social Responsiveness Scale - Parent version(Assessed at baseline.)
- Social Phobia and Anxiety Inventory (SPAI) - Parent version(Assessed at baseline, Mid-3 weeks, Mid-6 weeks, Mid-9 weeks, 12 weeks after treatment starts and 6 months after treatment has ended)
- Social Phobia Weekly Summary Scale (SPWSS)(Assessed at baseline, Mid-3 weeks, Mid-6 weeks, Mid-9 weeks, 12 weeks after treatment starts and 6 months after treatment has ended)
- Unintended treatment effects(Assessed at 12 weeks after treatment starts)
- Technology acceptance scale (TAS) - child version(Assessed at Mid-3 week and 12 weeks after treatment starts)
- Revised Children´s Anxiety and Depression Scale (RCADS) - Parent version(Assessed at baseline, mid-6 weeks, 12 weeks after treatment starts and 6 months after treatment has ended)
- Patient ICBT Adherence Scale (PIAS)(Assessed at Mid-6 weeks and 12 weeks after treatment starts)
- Education, Work and Social Adjustment Scale - parent version(Assessed at baseline, Mid-6 week, 12 weeks after treatment starts and 6 months after treatment has ended)
- Attention bias when presented with social stimuli (eye-tracking)(Assessed at baseline, 12 weeks after treatment starts and 6 months after treatment has ended)
- Qualitative interviews of experience from treatment(Assessed at 12 weeks after treatment starts)